BM8 fundamentals
Key facts
Market capitalization12.66 BEUR
Basic EPS (TTM)2.17EUR
Founded1997
Employees (FY)3.04 K
CEOAlexander Hardy
Websitebiomarin.com
About
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
3%
7%
11%
15%
19%
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
0.00
200.00 M
400.00 M
600.00 M
800.00 M
Revenue
Net income
Net margin %
Revenue breakdown
Revenue streams and regions a business earns money from
Estimates
Revenue and Earnings forecasts and estimates accuracy
Dividends
Dividend yield, history and sustainability
BM8 does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future
Financial health
Financial position and solvency of the company